ARTICLE | Company News
Zynaxis other research news
May 6, 1996 7:00 AM UTC
ZNXS received a $100,000 Phase I SBIR from the National Heart Lung and Blood Institute to develop delivery systems using the Zyn-Linker technology to treat restenosis. The goal of the six-month projec...